BioBridge + VLNT for Lymphedema
Trial Summary
What is the purpose of this trial?
This trial is testing if adding BioBridge, a biodegradable mesh made from pig collagen, to standard surgery can help patients with upper arm lymphedema. The mesh supports new lymph nodes to improve fluid drainage and reduce swelling. BioBlanket Surgical Mesh, a collagen-based surgical mesh, has been evaluated for its potential to facilitate soft tissue repair in an animal model.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are currently receiving chemotherapy or radiation therapy, you cannot participate in the trial.
What data supports the effectiveness of the treatment BioBridge + VLNT for Lymphedema?
The research highlights the importance of reliable monitoring and successful outcomes in procedures involving vascularized tissue transfer, like VLNT, which is part of the BioBridge + VLNT treatment. Although not directly related to lymphedema, the studies suggest that vascularized transfers are effective in complex reconstructions, indicating potential benefits for lymphedema treatment.12345
Is the BioBridge + VLNT treatment generally safe for humans?
Vascularized lymph node transfer (VLNT) is a surgical treatment for lymphedema that is gaining popularity, but it is associated with a risk of causing lymphedema in other areas (iatrogenic lymphedema). Efforts are being made to minimize complications, such as using specific techniques to reduce risks at the donor site.678910
How is the treatment Vascularized Lymph Node Transfer (VLNT) unique for lymphedema?
Vascularized Lymph Node Transfer (VLNT) is a surgical treatment that involves transferring healthy lymph nodes to the affected area to help reduce swelling and improve lymphatic drainage. Unlike other treatments, VLNT is a relatively novel technique that can provide long-term relief by restoring the lymphatic system, although it may take time to show effects.79111213
Research Team
Dung H Nguyen, MD, PharmD
Principal Investigator
Stanford University
Eligibility Criteria
This trial is for breast cancer survivors aged 18-75 with Stage I-II upper limb lymphedema after treatment, who've completed a full course of decongestive therapy. Participants must be free of cancer for 3 years, have no severe organ dysfunction or clotting disorders, not be pregnant or nursing, and able to undergo surgery.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Surgical Treatment
Participants undergo vascularized lymph node transplant surgery, with or without BioBridge Collagen Matrix implantation
Follow-up
Participants are monitored for changes in excess limb volume, quality of life, lymphatic function, and histological architecture
Treatment Details
Interventions
- BioBridge® Collagen Matrix
- Vascularized Lymph Node Transfer (VLNT)
Vascularized Lymph Node Transfer (VLNT) is already approved in United States, European Union, Canada, Japan for the following indications:
- Upper extremity lymphedema
- Lower extremity lymphedema
- Upper extremity lymphedema
- Lower extremity lymphedema
- Breast cancer-related lymphedema
- Upper extremity lymphedema
- Lower extremity lymphedema
- Upper extremity lymphedema
- Lower extremity lymphedema
Find a Clinic Near You
Who Is Running the Clinical Trial?
Fibralign Corporation
Lead Sponsor
Stanford University
Collaborator